Clinical Drug Investigation

, Volume 27, Issue 3, pp 149–161 | Cite as

Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease

Implications of Clinical Trials
  • Adrian J. B. Brady
Review Article


The renin-angiotensin-aldosterone system (RAAS) is now known to play a key role in the pathogenesis of hypertension and a range of other cardiovascular diseases. Two groups of drugs, the ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been developed with the aim of improving clinical outcomes by regulating the RAAS in patients with cardiovascular disease.

Initial assumptions were that these two drug types might be interchangeable, but ongoing research has revealed differences between them in terms of pharmacology and outcomes in clinical trials. Although both groups of drugs lower blood pressure, studies of the ACE inhibitor perindopril have revealed preservation of beneficial vascular and endothelial effects mediated by bradykinin and nitric oxide. The selective blockade exerted by ARBs is not associated with these effects. Furthermore, examination of clinical endpoints in major clinical trials has provoked discussion about outcomes comparing ACE inhibitors and ARBs, with recent debate focusing on the incidence of myocardial infarction (MI) in patients receiving these agents. Whether there is an actual difference in protection from MI remains unresolved, although available data confirm the benefit and safety of ACE inhibitors, in particular perindopril, for myocardial protection.


Losartan Amlodipine Bradykinin Valsartan Telmisartan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Preparation of this manuscript was supported by Servier. Editorial assistance was provided by WK Health Medical Communications.


  1. 1.
    Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005; 3: 15–29PubMedCrossRefGoogle Scholar
  2. 2.
    Lévy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109: 8–13PubMedCrossRefGoogle Scholar
  3. 3.
    Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287: H435–H446PubMedCrossRefGoogle Scholar
  4. 4.
    Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33: 613–21PubMedCrossRefGoogle Scholar
  5. 5.
    Matsubara H. Pathophysiological role of angiotensin II type 2 receptors in cardiovascular and renal diseases. Circ Res 1998; 83: 1182–91PubMedCrossRefGoogle Scholar
  6. 6.
    Siragy HM. The role of the AT2 receptor in hypertension. Am J Hypertens 2000; 13 (Suppl. 5 Pt 2): 62S–67SPubMedCrossRefGoogle Scholar
  7. 7.
    Carey RM, Wang Z-Q, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155–63PubMedCrossRefGoogle Scholar
  8. 8.
    Carey RM, Jin XH, Siragy HM. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 2001; 14 (Suppl. 6 Pt 2): 98S–102SPubMedCrossRefGoogle Scholar
  9. 9.
    Strauss MH, Lonn EM, Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists’ Collaboration. Eur Heart J 2005; 26: 2351–3PubMedCrossRefGoogle Scholar
  10. 10.
    Verdecchia P, Angeli F, Gattobigio R, et al. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26: 2381–6PubMedCrossRefGoogle Scholar
  11. 11.
    Alfakih K, Maqbool A, Sivananthan M, et al. Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (−1332 G/A) in patients with systemic hypertension. Hypertension 2004; 43: 1189–94PubMedCrossRefGoogle Scholar
  12. 12.
    Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004; 20: 1559–69PubMedCrossRefGoogle Scholar
  13. 13.
    Ichihara S, Senbonmatsu T, Price E Jr, et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001; 104: 346–51PubMedCrossRefGoogle Scholar
  14. 14.
    López-Sendón J, Swedberg K, McMurray J, et al. Task Force on ACE-inhibitors of the European Society of Cardiology: expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J 2004; 25: 1454–70PubMedCrossRefGoogle Scholar
  15. 15.
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial —the Losartan Heart Failure Survival Study, ELITE II. Lancet 2000; 355: 1582–7PubMedCrossRefGoogle Scholar
  16. 16.
    Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group: effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial —Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60PubMedCrossRefGoogle Scholar
  17. 17.
    Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction [letter]. BMJ 2004; 329: 1248–9PubMedCrossRefGoogle Scholar
  18. 18.
    McDonald MA, Simpson SH, Ezekowitz JA, et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005; 331: 873–78PubMedCrossRefGoogle Scholar
  19. 19.
    Cheung BMY, Cheung GTY, Lauder IJ, et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens 2006; 20: 37–43PubMedCrossRefGoogle Scholar
  20. 20.
    Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees: effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors —the CHARM-Alternative trial. Lancet 2003; 362: 772–6PubMedCrossRefGoogle Scholar
  21. 21.
    McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees: effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors —the CHARM-Added trial. Lancet 2003; 362: 767–71PubMedCrossRefGoogle Scholar
  22. 22.
    Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees: effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction —the CHARM-Preserved Trial. Lancet 2003; 362: 777–81PubMedCrossRefGoogle Scholar
  23. 23.
    Bussien JP, d’Amore TF, Perret L, et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther 1986; 39: 554–8PubMedCrossRefGoogle Scholar
  24. 24.
    Zhuo JL, Mendelsohn FAO, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39: 634–8PubMedCrossRefGoogle Scholar
  25. 25.
    Su JB, Barbe F, Crozatier B, et al. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol 1999; 34: 700–10PubMedCrossRefGoogle Scholar
  26. 26.
    Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 1994; 87: 567–74Google Scholar
  27. 27.
    Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439–49PubMedCrossRefGoogle Scholar
  28. 28.
    EUROPA Investigators. The European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators: efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease —randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8CrossRefGoogle Scholar
  29. 29.
    Ferrari R. PERTINENT: PERindopril, Thrombosis, InflammatioN, Endothelial dysfunction and Neurohormonal activation Trial, a sub-analysis of EUROPA [abstract 2585]. Annual Congress of the European Society of Cardiology. 2004; Aug 28–Sep 1: Munich, GermanyGoogle Scholar
  30. 30.
    Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension 2004; 43: 163–8PubMedCrossRefGoogle Scholar
  31. 31.
    Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48: 80–6PubMedCrossRefGoogle Scholar
  32. 32.
    Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941–50PubMedCrossRefGoogle Scholar
  33. 33.
    Kool MJ, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination amiloride + hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995; 13: 839–48PubMedCrossRefGoogle Scholar
  34. 34.
    Thybo NK, Stephens N, Cooper A, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (4 Pt 2): 474–81PubMedCrossRefGoogle Scholar
  35. 35.
    Buus NH, Bøttcher M, Jørgensen CG, et al. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or β-blockade in patients with essential hypertension. Hypertension 2004; 44: 465–70PubMedCrossRefGoogle Scholar
  36. 36.
    Schwartzkopff B, Brehm M, Mundhenke M, et al. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220–5PubMedCrossRefGoogle Scholar
  37. 37.
    Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987–92PubMedCrossRefGoogle Scholar
  38. 38.
    Hui Y, Dai Z, Chen X, et al. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Chin Med J (Engl) 1995; 108: 678–81PubMedGoogle Scholar
  39. 39.
    Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators: effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome —results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med 2006; 166: 659–66PubMedCrossRefGoogle Scholar
  40. 40.
    Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–6PubMedCrossRefGoogle Scholar
  41. 41.
    Fennessy PA, Campbell JH, Mendelsohn FA, et al. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996; 23: S30–2PubMedCrossRefGoogle Scholar
  42. 42.
    Ferrari R. Effect of ACE inhibition on myocardial ischaemia. Eur Heart J 1998; 19Suppl. J: J30–5PubMedGoogle Scholar
  43. 43.
    Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required plus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906PubMedCrossRefGoogle Scholar
  44. 44.
    Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1(2): 113–9PubMedCrossRefGoogle Scholar
  45. 45.
    Curran MP, McCormack PL, Simpson D. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease. Drugs 2006; 66: 235–56PubMedCrossRefGoogle Scholar
  46. 46.
    Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907–13PubMedCrossRefGoogle Scholar
  47. 47.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97CrossRefGoogle Scholar
  48. 48.
    Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581–8PubMedCrossRefGoogle Scholar
  49. 49.
    Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: atherosclerosis risk in communities study. N Engl J Med 2000; 342: 905–12PubMedCrossRefGoogle Scholar
  50. 50.
    Gupta AK. Determinants of new onset diabetes among hypertensive patients randomized in the ASCOT-BPLA trial [abstract]. World Congress of Cardiology; 2006 Sep 2–6, BarcelonaGoogle Scholar
  51. 51.
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003PubMedCrossRefGoogle Scholar
  52. 52.
    Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53PubMedCrossRefGoogle Scholar
  53. 53.
    Julius S, Kjeldsen SE, Weber M, et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31PubMedCrossRefGoogle Scholar
  54. 54.
    Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86PubMedCrossRefGoogle Scholar
  55. 55.
    McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47: 726–33PubMedCrossRefGoogle Scholar
  56. 56.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906PubMedCrossRefGoogle Scholar
  57. 57.
    Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 2005; 23: 2113–8PubMedCrossRefGoogle Scholar
  58. 58.
    Epstein BJ, Gums JG. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann Pharmacother 2005; 39: 470–80PubMedCrossRefGoogle Scholar
  59. 59.
    Turnbull F. New evidence of blood pressure-independent effects for agents acting via the renin-angiotensin system: analyses from the Blood Pressure Lowering Treatment Trialists’ Collaboration [abstract]. Program and abstracts from the Fifteenth European Meeting on Hypertension, June 17–21, 2005, Milan, ItalyGoogle Scholar
  60. 60.
    Zhang H, Thijs L, Staessen JA. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 2006; 48: 187–95PubMedCrossRefGoogle Scholar
  61. 61.
    Strauss MH, Hall A. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114: 838–54PubMedCrossRefGoogle Scholar
  62. 62.
    National Institute for Health and Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care (partial update). NICE guideline: draft for consultation. London: February 2006 [online]. Available from URL: [Accessed 2006 Nov 17]
  63. 63.
    National Institute for Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care. Clinical guideline 18. London: August 2004 [online]. Available from URL: [Accessed 2006 Nov 17]
  64. 64.
    US Dept of Health and Human Services. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. National Institutes of Health, National Heart, Lung, and Blood Institute National High Blood pressure Education Program. NIH Publication No. 04-5230, August 2004 [online]. Available from URL: [Accessed 2006 Nov 17]
  65. 65.
    PROGRESS Collaborative Group. Effects of a perindoprilbased blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475–84Google Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Adrian J. B. Brady
    • 1
  1. 1.Department of Medical CardiologyGlasgow Royal InfirmaryGlasgowScotland

Personalised recommendations